SuzanneKafajaMD
Rheumatology • Los Angeles, CAAssociate Clinical Professor/ Director Scleroderma Clinical Trials
Dr. Kafaja is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 UCLA Medical Plz Ste 365c
Los Angeles, CA 90095Phone+1 310-825-2448Fax+1 310-206-8606
Summary
- Suzanne Kafaja, MD is a rheumatologist based in Los Angeles, CA, with experience in treating connective tissue diseases and psoriatic arthritis, among other conditions. She completed her fellowship and residency at UCLA David Geffen School of Medicine/UCLA Medical Center and Olive View/UCLA Medical Center, respectively, and she currently serves as an Associate Clinical Professor at David Geffen School of Medicine at UCLA. Dr. Kafaja has numerous publications in her field and is involved in various clinical trials aimed at treating Diffuse Cutaneous Systemic Sclerosis. She is also an award-winning physician, having received the Scleroderma Spirit Leadership Award in 2018.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Rheumatology, 2008 - 2010
Olive View/UCLA Medical CenterResidency, Internal Medicine, 2005 - 2007
David Geffen School of Medicine at UCLAClass of 2001
Certifications & Licensure
CA State Medical License 2006 - 2026
American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Scleroderma Spirit Leadership Award The Scleroderma Foundation, 2018
Clinical Trials
- Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Start of enrollment: 2017 Jan 01
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis Start of enrollment: 2021 Feb 05
- Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis Start of enrollment: 2020 Jun 11
Publications & Presentations
PubMed
- Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Te...George E Georges, Dinesh Khanna, Mark H Wener, Matthew G Mei, Maureen D Mayes
Arthritis & Rheumatology. 2024-12-03 - Racial variability in immune responses only partially explains differential systemic sclerosis disease severity.Kamini E Kuchinad, Ji Soo Kim, Adrianne Woods, Gwen Leatherman, Laura Gutierrez-Alamillo
Annals of the Rheumatic Diseases. 2024-10-21 - 11 citationsEfficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.Robert Spiera, Masataka Kuwana, Dinesh Khanna, Laura Hummers, Tracy M Frech
Arthritis & Rheumatology. 2023-09-01
Journal Articles
- The Scleroderma Patient-Centered Intervention Network Cohort: Baseline Clinical Features and Comparison with Other Large Scleroderma CohortsDaniel E Furst, Robert Spiera, Maureen D Mayes, Lorinda Chung, Suzanne Kafaja, Virginia Steen, Shervin Assassi, Monique Hinchcliff, Rheumatology
Committees
- Medical Advisor, Medical Advisory board of Scleroderma Foundation of California 2023 - Present
- Scientific Abstract Review Committee, National Scleroderma Foundation 2022 - Present
Research History
- Medical Director, UCLA Scleroderma Clinical TrialsSince completing my fellowship in rheumatology in 2010, I had in depth training in systemic sclerosis. Since then I have been the PI and co investigator of major clinical trials in this field . I currently direct the. Scleroderma Clinical Trials at UCLA.2022 - Present
Professional Memberships
- Member
- Clinical Member
Other Languages
- Arabic, French, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
